REUTERS/Fred Prouser
Carlyle Group co-founder and Managing Director David Rubenstein
- Wall Street is interested in the companies that help drugmakers research and develop drugs.
- These companies, called contract research organizations, are becoming increasingly important for the pharmaceutical industry as companies look to save money on R&D.
Wall Street has been piling in to an area in healthcare you've likely never heard of.
Contract research organizations, or CROs for short, work with drugmakers to take on some of the science companies have to do to get drugs approved.
That means everything from discovering potential drug targets to running clinical trials on behalf of pharmaceutical companies.
For example, say you need to run a clinical trial for a drug you're working on, but you don't want to invest in hiring all the folks to run the clinical trial yourself. So you work with a CRO, which can set that up for you and recruit patients for a certain price. As drug companies continue to look for ways to trim R&D costs, these companies have become more popular.
That activity has made a lot of room for mergers and acquisitions, even at a time when drugmakers themselves are in a bit of a dealmaking lull. According to Bloomberg that M&A spending in the CRO industry was $24 billion in 2016. So far in 2017, the spending on deals is $13 billion.
Many of these CROs are getting picked up by private equity, signaling that investors expect the companies to grow over the next decade. Pamplona Capital Management, Carlyle Group and GTCR have all struck big deals in the space recently.
Stocks of the companies that are public are up more than 25% over the past year meanwhile, signaling public market investors are betting on the companies too, potentially in anticipation of activity to come
"We are at the beginning of this process," KPMG principal Paul Saias told Bloomberg.
Almost every major CRO has been involved with an acquisition, starting back in 2015.
- Pamplona Capital Management acquired Parexel International in a $5 billion deal to take the CRO private in June.
- In June, Albany Molecular Research Inc. was acquired and taken private by Carlyle Group and GTCR for $922 billion.
- Chiltern picked up a Japanese CRO Integrated Development Associates in May.
- In May, two of the largest CROs - INC Research Holdings and InVentiv Health - merged in a $4.6 billion deal.
- In 2016, Charles River Laboratories went on an acquisition spree, snapping up other CROs.
- In 2016, Quintiles Transitional merged with IMS Health in a $8.75 deal. Together, the company provides clinical research and health information technologies, which goes beyond what's traditionally considered a CRO.
- Back in 2015, LabCorp acquired Covance in a $6.2 billion deal.
Only two of the top 10 CROs appear to not be part of the dealmaking frenzy: Pharmaceutical Product Development, which is majority owned by the Carlyle Group, which was also behind taking Albany Molecular private. The other is Icon, which might be more open to deals now, according to Jefferies analyst David Windley.